Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BulgariaBack to Bulgaria

Clinical trials in Panagyurishte – page 3

46 clinical trials in Panagyurishte, Bulgaria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Panagyurishte at a glance
46
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

46 trials in Panagyurishte

Open in trial search

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Small cell lung cancer extensive stage

Not recruiting

Study of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Hormone-dependent prostate cancer+1

Not recruiting

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Squamous cell carcinoma of head and neck

Not recruiting

Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Inhibrx Biosciences Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Chronic obstructive pulmonary disease

Not recruiting

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:BAY 2927088
  • Sponsor:Bayer AG

Non-small cell lung cancer+2

Not recruiting

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Other cities in Bulgaria

The busiest research cities in the country

All 53 cities in Bulgaria

Clinical research in Panagyurishte

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments, including studies of novel therapies for both non-small cell and small cell variants. Research encompasses targeted treatments for patients with specific genetic mutations.

  • Advanced NSCLC Studies
  • SCLC Treatment Innovations
  • Targeted Therapy Research

Additional focus on breast cancer, head and neck cancers, and renal cell carcinoma treatments.

02 Cardiovascular Studies

Groundbreaking research in heart failure prevention and treatment of acute coronary syndrome. Studies evaluate new combination therapies and preventive approaches.

  • Heart Failure Prevention
  • Cardiovascular Risk Management
  • Post-Heart Attack Care

Trials focus on reducing cardiovascular events and improving patient outcomes.

03 Neurological Research

Advanced studies in multiple sclerosis treatment, exploring new therapeutic approaches and comparing treatment efficacy. Research includes both relapsing-remitting and progressive forms.

  • MS Treatment Innovations
  • Disease Progression Studies
  • Comparative Treatment Research

Emphasis on improving patient outcomes and quality of life.

Back to BulgariaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.